FDA Approves Lurbinectedin in Combination with Atezolizumab or Atezolizumab and Hyaluronidase-tqjs for Extensive Stage SCLC By Ogkologos - October 16, 2025 87 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the IMforte study Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR Survivor Story: Erin June 4, 2021 Insulin Resistance May Contribute to Poorer Breast Cancer Outcomes, Study Says June 2, 2020 Shelter Cat Who Battled Breast Cancer Seeks Fellow Survivor to Give... October 30, 2019 How to Spot Suspicious Herb and Supplement Claims During Cancer June 29, 2021 Load more HOT NEWS FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head... Can AI Help Predict Which Cancer Patients Should Be Treated with... TG4001 Therapeutic Vaccination Plus Avelumab-Mediated PD-L1 Blockade Improves Tumour Microenvironment in... Foodie Friday: Watermelon Fruit Pizza
